Market Opportunity: Management of Diabetes. Outside of the insulin pump market, we face competition from a number of companies, medical researchers and pharmaceutical companies that offer or are pursuing competing delivery devices, technologies and procedures, such as prefilled insulin syringes, insulin pens and inhalable insulin products, as well as companies with approved therapeutics or in-development therapeutic candidates impacting diabetes. Our current primary competitors are publicly trad...
Q2 FY2026 — expected 2026-07-28
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-067065 | EDGAR | 113K words |
| 2025-03-25 | 2024-12-31 | 0000950170-25-044516 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-28 | 2025-09-30 | 0001193125-25-253538 | EDGAR | 91K words |
| 2025-07-29 | 2025-06-30 | 0000950170-25-099652 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064504 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-17 | 0001171843-26-000859 | EDGAR | 5K words |
| 2026-01-30 | 0001171843-26-000538 | EDGAR | — |
| 2026-01-08 | 0001171843-26-000145 | EDGAR | — |
| 2025-10-28 | 0001171843-25-006720 | EDGAR | — |
| 2025-07-29 | 0001171843-25-004780 | EDGAR | — |
| 2025-06-23 | 0001171843-25-004016 | EDGAR | — |
| 2025-05-06 | 0001171843-25-002817 | EDGAR | — |
| 2025-03-27 | 0001171843-25-001785 | EDGAR | — |
| 2025-03-25 | 0001171843-25-001690 | EDGAR | — |
| 2025-01-31 | 0001193125-25-018471 | EDGAR | — |
20 total filings indexed. 5 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001674632 |
| Ticker | BBNX |
| Exchange | Nasdaq |
| SIC | 3841: Surgical & Medical Instruments & Apparatus |
| Incorporated | DE |
| Website | https://www.betabionics.com |
| Listed | 2025-01-30 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report